This federal Project Grant award from the U.S. Department of Health and Human Services' National Cancer Institute provides $547,519 to Oregon Health & Science University (OHSU) to leverage biologically-specific PET/MRI monitoring and therapeutic modulation of the hypoxic glioblastoma tumor immune microenvironment (TIME) in order to improve outcomes for patients with glioblastoma, an aggressive form of brain cancer.
The key objectives are to: 1) Define a biologically-specific imaging measure of the immunosuppressive hypoxic TIME using a novel iron nanoparticle enhanced PET/MRI technique called SELFI (segregation and extravascular localization of ferumoxytol imaging) to quantify the hypoxic fraction; and 2) Determine the effect of tumor-associated macrophage (TAM) modulators on the TIME of glioblastoma using syngeneic and patient-derived xenograft animal models.
This research is funded under the 21st Century Cures Act - Beau Biden Cancer Moonshot program (CFDA 93.353) and is expected to run from May 1, 2024 through April 30, 2029. Successful outcomes could provide evidence-based proof of principle for further development and clinical trials of TAM-based immunotherapeutic techniques for glioblastoma.
Generated 5/14/24, 11:28 AM